PDCD1 and melanoma: One of these will employ it in conjunction with tumor infiltrating lymphocyte (TIL) therapy (NCT04217473) for patients with advanced melanoma and an additional trial is expected where the TILT-123 virus will be combined with antiprogrammed death ligand-1 (PD-L1) and anti-PD-1 antibodies for patients with advanced melanoma and other solid tumors.